Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- 08 Feb 2023 Status changed from recruiting to completed.
- 22 Jul 2021 Planned End Date changed from 1 Nov 2019 to 1 Dec 2021.
- 22 Jul 2021 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2021.